drugset / Trial / NCT05859477
Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
The goal of this phase 2 clinical trial is to evaluate the efficacy of nivolumab in combination with CAPOX in patients with FGFR2-positive/PD-L1-positive/HER2-negative metastatic gastric cancer.
Timeline
- Start
- 2022-06-05
- Primary completion
- 2023-12-01
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Nivolumab | Monoclonal antibody | 360 mg | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |